Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 9.37
(-0.85%)
CNY 9.37
(-0.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 138.93 Million CNY | -8.85% |
| 2022 | 152.42 Million CNY | -61.87% |
| 2021 | 399.76 Million CNY | -0.32% |
| 2020 | 401.06 Million CNY | 21.18% |
| 2019 | 330.97 Million CNY | 160.96% |
| 2018 | 126.82 Million CNY | 18.67% |
| 2017 | 106.87 Million CNY | 14.4% |
| 2016 | 93.41 Million CNY | -0.28% |
| 2015 | 93.67 Million CNY | 24.88% |
| 2014 | 75.01 Million CNY | 6.11% |
| 2013 | 70.69 Million CNY | 89.6% |
| 2012 | 37.28 Million CNY | -51.73% |
| 2011 | 77.23 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 28.39 Million CNY | -33.79% |
| 2024 Q3 | 397.07 Thousand CNY | -98.6% |
| 2024 Q1 | 42.88 Million CNY | 167.63% |
| 2023 Q3 | 8.52 Million CNY | -66.04% |
| 2023 Q4 | 16.02 Million CNY | 88.02% |
| 2023 FY | 138.93 Million CNY | -8.85% |
| 2023 Q1 | 9.9 Million CNY | 110.0% |
| 2023 Q2 | 25.09 Million CNY | 153.48% |
| 2022 Q4 | -99.05 Million CNY | -989.28% |
| 2022 Q3 | -9.09 Million CNY | 47.45% |
| 2022 Q2 | -17.3 Million CNY | -118.49% |
| 2022 Q1 | 93.57 Million CNY | -24.19% |
| 2022 FY | 152.42 Million CNY | -61.87% |
| 2021 Q3 | 74.71 Million CNY | -38.61% |
| 2021 FY | 399.76 Million CNY | -0.32% |
| 2021 Q1 | 79.92 Million CNY | 112.72% |
| 2021 Q2 | 121.69 Million CNY | 52.25% |
| 2021 Q4 | 123.43 Million CNY | 65.21% |
| 2020 Q1 | 62.03 Million CNY | 33.44% |
| 2020 Q3 | 72.46 Million CNY | -40.53% |
| 2020 FY | 401.06 Million CNY | 21.18% |
| 2020 Q2 | 121.85 Million CNY | 96.44% |
| 2020 Q4 | 37.57 Million CNY | -48.15% |
| 2019 Q2 | 68.95 Million CNY | 30.43% |
| 2019 FY | 330.97 Million CNY | 160.96% |
| 2019 Q4 | 46.49 Million CNY | -25.02% |
| 2019 Q3 | 62 Million CNY | -10.08% |
| 2019 Q1 | 52.86 Million CNY | 347.9% |
| 2018 Q2 | 52.67 Million CNY | 78.79% |
| 2018 Q1 | 29.46 Million CNY | 30.34% |
| 2018 FY | 126.82 Million CNY | 18.67% |
| 2018 Q4 | 11.8 Million CNY | -64.12% |
| 2018 Q3 | 32.89 Million CNY | -37.55% |
| 2017 FY | 106.87 Million CNY | 14.4% |
| 2017 Q2 | 32.29 Million CNY | -6.12% |
| 2017 Q3 | 17.57 Million CNY | -45.56% |
| 2017 Q4 | 22.6 Million CNY | 28.58% |
| 2017 Q1 | 34.39 Million CNY | 128.93% |
| 2016 Q3 | 18.23 Million CNY | -34.84% |
| 2016 Q2 | 27.98 Million CNY | -12.99% |
| 2016 Q4 | 15.02 Million CNY | -17.61% |
| 2016 FY | 93.41 Million CNY | -0.28% |
| 2016 Q1 | 32.16 Million CNY | 23.32% |
| 2015 Q1 | 40.98 Million CNY | 9.54% |
| 2015 FY | 93.67 Million CNY | 24.88% |
| 2015 Q4 | 26.08 Million CNY | 232.12% |
| 2015 Q3 | 7.85 Million CNY | -58.12% |
| 2015 Q2 | 18.75 Million CNY | -54.24% |
| 2014 Q4 | 37.41 Million CNY | 0.0% |
| 2014 FY | 75.01 Million CNY | 6.11% |
| 2013 FY | 70.69 Million CNY | 89.6% |
| 2012 FY | 37.28 Million CNY | -51.73% |
| 2011 FY | 77.23 Million CNY | 0.0% |